Stem Cell Therapy in India
Stem cell therapy in India from $5,000. Autologous & mesenchymal stem cells for neurological & orthopedic conditions. ICMR-regulated at NeuroGen & Plexus centers.
Estimated cost: $5,000 – $10,000 · Average stay: 7–10 days
Stem cell therapy — the therapeutic use of stem cells to treat or prevent disease or promote healing — represents one of the most active and rapidly evolving frontiers in modern medicine. Stem cells have the unique ability to differentiate into many different cell types and to promote healing through paracrine effects (releasing growth factors and anti-inflammatory mediators that support tissue repair). For patients with neurological, orthopedic, and systemic conditions where conventional treatments have provided limited benefit, stem cell therapy offers a biologically based approach to promoting regeneration and functional improvement.
It is important to approach stem cell therapy with realistic expectations grounded in evidence. Some applications of stem cell therapy are well-established: hematopoietic stem cell transplantation (bone marrow transplant) for blood cancers and inherited bone marrow disorders is a curative treatment with decades of clinical data. Orthopedic applications — platelet-rich plasma (PRP) and mesenchymal stem cell injections for osteoarthritis, tendon injuries, and cartilage defects — have an expanding evidence base and reasonable safety profiles. Neurological applications — for conditions including cerebral palsy, autism spectrum disorder, spinal cord injury, amyotrophic lateral sclerosis (ALS), and multiple sclerosis — are at an earlier evidence stage and should be pursued with careful patient selection, realistic outcome expectations, and at regulated centers using ethically sourced cells.
India has several ICMR (Indian Council of Medical Research)-registered stem cell therapy centers that operate under the New Drugs and Clinical Trials Rules, 2019, which provide a regulatory framework for stem cell-based therapies in India. NeuroGen Brain and Spine Institute in Mumbai, led by Dr. Alok Sharma, is one of the most published and internationally recognized centers for stem cell therapy for neurological conditions in South Asia. Plexus Neuro and Stem Cell Research Centre in Bengaluru is another ICMR-registered facility with an active clinical research program.
The cost of stem cell therapy in India — $5,000–$10,000 for a treatment course depending on the condition and protocol — is significantly lower than equivalent programs in the United States ($15,000–$30,000) or Germany ($20,000–$40,000). Gaf Healthcare facilitates stem cell therapy referrals exclusively to ICMR-registered, ethically compliant centers that can provide documentation of regulatory compliance, cell sourcing standards, and published clinical outcome data.
We strongly advise every prospective stem cell therapy patient to approach this treatment with a commitment to understanding the evidence for their specific condition, to having realistic expectations, and to verifying that any center they consider is regulated by the appropriate national authority — the ICMR in India — and does not make promises that exceed the current state of scientific evidence.
Types of Stem Cells Used in Therapy
Stem cells used therapeutically in India come from several sources, each with distinct biological properties and regulatory considerations:
Autologous stem cells — derived from the patient's own body (bone marrow, peripheral blood, or adipose tissue) — carry no risk of immune rejection because they are recognized as self. They are the safest type from an immunological perspective. Autologous hematopoietic stem cell transplantation (for multiple myeloma, lymphoma) and autologous mesenchymal stem cell therapy (for orthopedic conditions) both use this approach.
Mesenchymal stem cells (MSCs) — derived from bone marrow, adipose tissue, or umbilical cord tissue — are multipotent cells that can differentiate into bone, cartilage, muscle, and fat cells, and that produce important paracrine factors promoting anti-inflammation and tissue repair. MSCs are the most widely studied cell type for therapeutic applications beyond the blood system, including neurological and orthopedic applications.
Umbilical cord blood stem cells — collected from the umbilical cord at birth — contain both hematopoietic and mesenchymal progenitor cells and have been used in allogeneic transplantation for blood disorders. Their use in neurological conditions remains investigational.
It is critical to distinguish between evidence-based applications with published outcomes data (e.g., MSCs for knee osteoarthritis, bone marrow transplant for blood disorders) and applications that remain under active investigation where efficacy has not been firmly established (many neurological applications). Gaf Healthcare provides honest guidance on the evidence status for each condition.
Who Is a Candidate for Stem Cell Therapy?
Stem cell therapy for neurological conditions remains largely investigational outside of well-defined haematological indications. Patients must carefully distinguish between evidence-based and experimental applications.
Established, evidence-based stem cell treatments: haematopoietic stem cell transplantation (HSCT) for leukaemia, lymphoma, multiple myeloma, and aplastic anaemia; autologous HSCT for multiple sclerosis (AHSCT - highest-quality evidence in younger patients with active inflammatory MS refractory to 2+ disease-modifying therapies).
Investigational applications where clinical trials provide the only appropriate access: mesenchymal stem cell (MSC) infusions for ALS/MND; MSC therapy for spinal cord injury; stem cells for Parkinson's disease. These approaches have biological plausibility and Phase I/II safety data but lack Phase III randomised controlled trial evidence of efficacy.
Patients must be extremely cautious of unregulated commercial stem cell clinics that offer treatments outside clinical trial frameworks - particularly for neurological conditions - as these carry significant risks with no evidence of benefit. Always request the trial registration number (ClinicalTrials.gov) and published outcome data.
How is Stem Cell Therapy Administered?
The stem cell therapy procedure varies significantly based on the source of cells, the condition being treated, and the protocol of the specific center. For autologous MSC therapy, the typical process involves: cell collection (bone marrow aspiration from the pelvis, or lipoaspiration from adipose tissue, under local or general anesthesia); cell processing in a GMP (Good Manufacturing Practice) laboratory certified to isolate, characterize, and expand the MSCs; and cell administration (intravenous infusion, intrathecal injection into the spinal fluid, direct injection into joints, or specific delivery routes depending on the target organ).
For neurological conditions (cerebral palsy, ALS, spinal cord injury), cells are typically administered via intrathecal injection (directly into the cerebrospinal fluid, allowing them to reach the central nervous system) or intravenous infusion with or without intrathecal delivery. The treatment protocol at NeuroGen and Plexus typically involves a series of cell administrations over several days, combined with an intensive multidisciplinary rehabilitation program (physiotherapy, occupational therapy, speech therapy, cognitive training) during the treatment period.
The biological basis of benefit in neurological conditions is not cell replacement (the numbers of cells used are too small to replace millions of damaged neurons) but rather paracrine effects — the cells secrete growth factors, anti-inflammatory cytokines, and survival factors that support existing neuronal populations, reduce inflammation, and promote endogenous repair mechanisms.
Procedure Steps
- Comprehensive pre-treatment evaluation: neurological assessment with standardized scales (GMFCS for cerebral palsy, ALSFRS-R for ALS, ASIA scale for spinal cord injury), brain/spinal MRI, blood tests.
- Eligibility assessment: patient's specific condition, severity, duration, prior treatments, and realistic outcome expectations discussed with treating neurologist.
- Cell sourcing: bone marrow aspiration under local anesthesia or sedation (50–100 mL from posterior iliac crest); cells transported to GMP laboratory.
- Cell processing: MSC isolation by density gradient centrifugation; cell characterization (flow cytometry confirms MSC phenotype); expansion if required; sterility and viability testing.
- Cell administration: typically 3–5 intrathecal injections and/or IV infusions given over 3–5 days; lumbar puncture technique used for intrathecal delivery.
- Intensive rehabilitation program: daily physiotherapy, occupational therapy, speech therapy (as indicated); goal-setting based on baseline assessment and expected response.
- Discharge with continuation rehabilitation program; follow-up assessment at three and six months using standardized outcome measures.
- Documentation of outcomes using validated scales allows contribution to the center's published clinical database and comparison against pre-treatment baseline.
Types of Stem Cell Therapy
Autologous Haematopoietic Stem Cell Transplant (Auto-HSCT)
The patient's own stem cells are harvested from peripheral blood (after G-CSF mobilisation), the patient receives high-dose chemotherapy to eliminate diseased cells, and the previously collected stem cells are reinfused to reconstitute the haematopoietic system. Used for leukaemia, lymphoma, myeloma (established), and active inflammatory MS. Avoids graft-versus-host disease.
Cost: $25,000 - $60,000
Allogeneic Haematopoietic Stem Cell Transplant (Allo-HSCT)
Stem cells from an HLA-matched related donor or matched unrelated donor (MUD) are infused after conditioning chemotherapy. The donor immune system provides a graft-versus-leukaemia (GvL) effect - key to curing high-risk haematological malignancies. Associated with graft-versus-host disease (GvHD) risk - the principal morbidity risk.
Cost: $40,000 - $100,000
MSC Infusion Therapy (Investigational - Neurological)
Mesenchymal stem cells derived from bone marrow, adipose tissue, or umbilical cord are expanded in GMP-certified laboratories and infused intravenously or intrathecally. MSCs are immunomodulatory and neuroprotective. Currently investigated for ALS, spinal cord injury, and MS in Phase I/II trials. Only appropriate within registered clinical trial frameworks.
Cost: $15,000 - $40,000 (trial participation costs)
Intrathecal Stem Cell Delivery
Stem cells are delivered directly into the cerebrospinal fluid via lumbar puncture, aiming to increase cell proximity to the spinal cord and brain. Used in some ALS and spinal cord injury trials to enhance neural bioavailability compared to systemic infusion. Not standard of care outside clinical trials.
Cost: $12,000 - $35,000
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
United States — $15,000 – $30,000 — Baseline
Germany — $20,000 – $40,000 — Similar to USA
Mexico / Panama — $12,000 – $25,000 — ~20% savings vs. USA
India — $5,000 – $10,000 — Up to 67% savings vs. USA
UAE — Not routinely available for neurological conditions — N/A
Stem cell therapy cost in India covers the cell processing in a GMP laboratory (the most expensive element), the cell administration procedures (intrathecal or IV), the rehabilitation program during the treatment period, and clinical assessment before and after treatment. The cost varies by cell dose, number of administrations, the duration of the in-hospital rehabilitation component, and whether autologous or allogeneic cells are used. Gaf Healthcare provides detailed cost breakdowns from our partner centers before any commitment.
Recovery & Follow-up
The stem cell therapy process itself — the cell administration phase — is generally well tolerated. Intrathecal injections may cause transient headache (post-dural puncture headache) in some patients, similar to what occurs after a spinal anesthetic; this resolves with rest and hydration over one to two days. Low-grade fever for 24–48 hours after cell infusion is occasionally seen and resolves spontaneously.
Functional improvements, where they occur, typically begin to be noticed two to four weeks after treatment and may continue to develop over three to six months as the paracrine effects of the cells propagate healing processes. Outcomes are measured using standardized validated scales at three and six months after treatment; these documented outcomes are compared against the patient's baseline assessment.
It is important to manage expectations honestly: published data shows that stem cell therapy for neurological conditions produces measurable improvements in a proportion of patients — particularly in children with cerebral palsy, where motor function improvements are documented in multiple series — but complete neurological recovery is not a realistic expectation for conditions involving irreversible neuronal loss.
Recovery Tips
- Commit to the full rehabilitation program during and after stem cell therapy — the therapy creates biological conditions for improvement; rehabilitation provides the functional practice that translates into actual skill gains.
- Set specific, measurable goals before treatment (e.g., sitting balance, hand function, communication milestones for children) so that outcome assessment is objective rather than subjective.
- Continue a structured home rehabilitation program after returning home — partner with a local physiotherapist or occupational therapist who can maintain the program established during treatment.
- Document progress with video recordings at baseline and at three months and six months — functional changes are often more visible on video than on formal scale scores.
- Attend the three-month and six-month follow-up assessments (remotely via video if returning to India is not feasible); these are critical for honest outcome documentation.
- Do not consider repeat treatment without objective evidence of meaningful benefit from the first treatment — repeat courses should be evidence-based, not hope-driven.
- Maintain realistic expectations — communicate these carefully to family members whose expectations may be higher than the evidence supports.
- Report any unexpected new symptoms promptly to the treatment center — while serious adverse events are rare, they need to be documented and investigated.
Risks & Complications
The safety profile of autologous MSC therapy is generally favorable — the cells are derived from the patient's own body, reducing the risk of immune reactions. The cell administration procedure itself carries the risks of any invasive procedure: lumbar puncture-related headache, infection (minimized by sterile technique), and theoretical tumorigenesis (though no human study has documented tumor formation from MSC therapy). Allogeneic cell products carry additional risks of immune reaction and, theoretically, graft-versus-host disease.
The ethical and practical risk of pursuing stem cell therapy at unregulated centers — clinics that operate without GMP facilities, without ethical oversight, without genuine clinical protocols, and sometimes without qualified medical staff — is significant. Harm from such centers has been documented globally. Gaf Healthcare's strict policy of referring only to ICMR-registered, published Indian centers is designed specifically to protect patients from these risks.
Why GAF Healthcare
Gaf Healthcare approaches stem cell therapy with particular care because this field attracts patients who are often desperate, are sometimes poorly informed about the state of scientific evidence, and are vulnerable to unscrupulous providers. Our role is to provide honest, evidence-based guidance; facilitate referrals to regulated centers with documented outcomes; and help families make informed decisions rather than decisions driven by hope alone.
Before arranging any stem cell therapy referral, our team reviews the specific condition, its severity, the available evidence for stem cell therapy in that condition, and the patient's prior treatment history. We provide a written summary of the current evidence before any commitment is made. We then coordinate the assessment, treatment, and outcome documentation process at our ICMR-registered partner centers.
Frequently Asked Questions
Is stem cell therapy a cure for neurological conditions?
For most neurological conditions currently being treated with stem cell therapy — including cerebral palsy, ALS, autism, and spinal cord injury — it is not a cure. Published outcomes show measurable functional improvements in motor skills, communication, and activities of daily living in a proportion of patients, particularly children. These improvements are meaningful for quality of life but fall short of cure in conditions involving irreversible neuronal damage. Honest expectation-setting before treatment is essential.
Which neurological conditions respond best to stem cell therapy?
The best-documented responses in India's published literature are in pediatric cerebral palsy, where multiple series show improvements in motor function (GMFCS scale), upper extremity function, and communication scores. Spinal cord injury (incomplete lesions with some preserved function) and multiple sclerosis have also shown measurable responses in some studies. ALS and autism show more variable responses. Conditions involving severe, long-standing irreversible neuronal loss (e.g., complete spinal cord injury, end-stage neurodegenerative diseases) are less likely to show meaningful improvement.
How do I verify that a stem cell center is legitimate?
In India, legitimate stem cell therapy centers for neurological applications should: be registered with ICMR under the Stem Cell Policy; have a GMP-certified cell processing laboratory; have ethical committee approval for their treatment protocols; publish their outcomes in peer-reviewed journals; and provide transparent, documented informed consent that includes honest discussion of the evidence limitations. Ask specifically for ICMR registration documents and published outcome papers. Gaf Healthcare verifies all of these criteria before working with any stem cell center.
How long is the treatment program?
The in-hospital treatment phase at centers like NeuroGen and Plexus typically spans four to eight weeks: one to two weeks of comprehensive pre-treatment assessment, one to two weeks of cell administration procedures, and two to four weeks of intensive multidisciplinary rehabilitation. The total India stay therefore ranges from four to eight weeks. Families should plan for a committed stay that includes the full rehabilitation component, which is inseparable from the cell therapy in driving outcomes.
Can stem cell therapy be combined with other treatments?
Yes, and at reputable Indian centers, it is always combined with intensive multidisciplinary rehabilitation. Stem cell therapy is not administered in isolation — the biological effects of the cells are maximized when the patient is simultaneously engaged in goal-directed physiotherapy, occupational therapy, and speech therapy that provides functional context for any neurological improvements. The rehabilitation component is not optional or supplementary — it is central to the treatment protocol.
Is stem cell therapy covered by health insurance?
In most countries, stem cell therapy for neurological conditions (cerebral palsy, ALS, autism, multiple sclerosis) is not covered by health insurance because it remains an investigational treatment without established efficacy from randomized controlled trials. Stem cell transplantation (bone marrow transplant) for blood cancers is a different matter — it is a standard of care and covered by most insurance plans. Patients considering stem cell therapy for neurological conditions should plan for out-of-pocket payment.